Clinical Trial of Molecular Biomarkers in Women With Uterine Cervix Cancer

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This is a phase 0 clinical trial of molecular biomarkers in women with uterine cervix cancer. Women receive standard-of-care radiochemotherapy followed by brachytherapy. Blood samples are obtained to detect circulating levels of deoxyribonucleotides, human papillomavirus DNA, and circulating tumor cells.

See also
Status	Clinical Trial	Phase
Completed	`NCT05022511` - Three Birds With One Stone	N/A
Not yet recruiting	`NCT06331468` - Hypofractionated Radiochemotherapy	Phase 2
Completed	`NCT03296566` - The SAFE Study: Satisfaction and Adherence to Follow-Up With Colposcopy Exams	N/A
Completed	`NCT02363829` - A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)	Phase 1

NCT number	NCT05462951
Study type	Interventional
Source	University of Kentucky
Contact	Yvonne Taul
Phone	859-323-2354
Email	yvonne.taul@uky.edu
Status	Recruiting
Phase	N/A
Start date	January 3, 2023
Completion date	December 31, 2024

Clinical Trial of Molecular Biomarkers in Women With Uterine Cervix Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms